SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
SanBio Company Limited (SNBIF) , forward earnings yield 322.58%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 0.3
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 32/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SNBIF
Valuation Multiples
P/E (TTM)0.0
Forward P/E0.3
PEG Ratio0.01
Forward PEG0.01
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-52.63
Forward EPS (Est.)$52.76
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield322.58%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-40.88 |
$949.54M |
$-1.84B |
-193.3% |
| 2018 |
$-86.85 |
$490.51M |
$-3.94B |
-803.3% |
| 2019 |
$-60.17 |
$741.61M |
$-2.92B |
-393.8% |
| 2020 |
$-100.91 |
$447.23M |
$-5.16B |
-1153.3% |
| 2021 |
$-65.38 |
$0.00 |
$-3.39B |
- |
| 2022 |
$-90.33 |
$0.00 |
$-4.68B |
- |
| 2023 |
$-95.99 |
$0.00 |
$-5.56B |
- |
| 2024 |
$-40.48 |
$0.00 |
$-2.64B |
- |
| 2025 |
$-41.85 |
$0.00 |
$-2.88B |
- |
| 2026 |
$-52.63 |
$0.00 |
$-3.84B |
- |
